At a glance
ClinicalIndex Comparison RecordN/ACompleted· 10 enrolled
Drug / intervention
Fludeoxyglucose F18 +2 moreradiation
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Pilot Study to Assess the Feasibility of Detection and Quantification of Differences in Hodgkin Lymphoma and Diffuse Large B-cell Lymphoma Using FDG-PET/CT Imaging
In Brief
A clinical study evaluating Fludeoxyglucose F18, Computed Tomography, and 1 other intervention for Lymphoma. Completed, enrolled 10 participants across 1 site.
Detailed Summary
RATIONALE: Imaging procedures, such as positron emission tomography or computed tomography, may help in detecting differences between Hodgkin lymphoma or diffuse large B-cell lymphoma cancer cells. PURPOSE: This clinical trial is studying positron emission tomogaphy and computed tomography in determining differences in Hodgkin lymphoma and diffuse large B-cell lymphoma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLymphoma
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartMay 2009
First PostedOct 2009
Primary CompletionJul 2013
Study CompletionNov 2014
TodayJul 2026
First PostedOct 30, 2009
Enrollment StartMay 1, 2009
Primary CompletionJul 1, 2013
Study CompletionNov 5, 2014
TodayJul 2, 2026
Enrollment to primary: 4.2 yearsPosted 16.7 years ago
Interventions
Fludeoxyglucose F18radiation
Undergo FDG PET/CT scans
Computed Tomographyprocedure
Undergo FDG PET/CT scans
Positron emission tomographyprocedure
Undergo FDG PET/CT scans